McKesson Corporation struggled in the third quarter, missing its revenue estimates due to weak sales in its U.S. pharmaceutical segment. Consequently, the company’s shares fell by 3% in extended trading.
About the Author
McKesson Corporation struggled in the third quarter, missing its revenue estimates due to weak sales in its U.S. pharmaceutical segment. Consequently, the company’s shares fell by 3% in extended trading.
